Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Resistance news

Show

From To
Transition to dolutegravir cost-effective in LMICs with high HIV drug resistance

In low- and middle-income countries, resistance to non-nucleoside reverse transcriptase inhibitors, or NNRTIs, is nearing and exceeding 10% in patients with HIV who are initiating or reinitiating first-line ART, according to recent data. A new modeling study showed that transitioning first-line ART from NNRTIs to dolutegravir may be a cost-effective way to reverse this increasing trend in resistance.

Published
13 December 2017
From
Healio
HIV drug resistance now high enough to trigger a change in first-line treatment in eastern and southern Africa

HIV drug resistance is increasing rapidly in southern and eastern Africa and Latin America and, as a result, it may soon be necessary to change the

Published
04 December 2017
By
Keith Alcorn
Rising levels of HIV drug resistance

HIV drug resistance is approaching and exceeding 10 percent in people living with HIV who are about to initiate or reinitiate first-line antiretroviral therapy, according to the largest meta-analysis to date on HIV drug resistance, led by researchers at UCL and the World Health Organization (WHO) and funded by the Bill & Melinda Gates Foundation and the WHO.

Published
01 December 2017
From
Eurekalert Inf Dis
BASHH welcomes publication of position statement on doxycycline as post-exposure prophylaxis for sexually transmitted infections

The British Association for Sexual Health and HIV (BASHH) has welcomed the publication of a new joint BASHH and Public Health England (PHE) position statement on the use of doxycycline as post-exposure prophylaxis (PEP) for sexually transmitted infections (STIs). A conference presentation had suggested that use of PEP with doxycycline was associated with a halving of the rates of bacterial STIs in men who have sex with men (MSM), in an extension of the French IPERGAY trial. However caution is advised.

Published
03 November 2017
From
BASHH
Uganda: ARVs Stock-Out Sparks Fear of Mass Drug Resistance

Civil society organisations and people living with HIV/Aids have warned that almost a million Ugandans could develop resistance to first-line anti-retroviral therapy if nothing is done about the nation-wide stock-out of drugs.

Published
01 November 2017
From
AllAfrica
Fostemsavir controls viral load in half of people with highly drug-resistant HIV

Fostemsavir, a new experimental attachment inhibitor, suppressed viral load in over half of participants with extensive drug resistance when added to a background regimen selected by resistance

Published
28 October 2017
By
Keith Alcorn
Boosted protease inhibitor and lamivudine provides effective maintenance treatment

HIV maintenance treatment with two drugs, a boosted protease inhibitor and lamivudine, is just as effective as three-drug treatment with a boosted protease inhibitor in people who

Published
26 October 2017
By
Keith Alcorn
Long-acting monoclonal antibody effective against multidrug-resistant HIV

Ibalizumab, a long-acting monoclonal antibody that prevents HIV from entering cells, maintained viral suppression for a year in people with highly resistant HIV and limited

Published
12 October 2017
By
Liz Highleyman
Antibody-Based HIV Tx Proves Durable

The monoclonal antibody HIV drug ibalizumab, designed for patients who've developed severe drug resistance, had long-lasting protection in the 24-week extension phase of a phase III trial, researchers reported here.

Published
10 October 2017
From
MedPage Today
Amsterdam PrEP failure patient had unusual course of HIV infection

At last February’s Conference on Retroviruses and Opportunistic Infections (CROI), Dutch clinicians presented a so-far unique case of a man who had apparently become infected

Published
02 October 2017
By
Gus Cairns
← First12345...36Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.